REC-617 for Leiomyosarcoma

This trial tests whether a new drug, REC-617, can help control leiomyosarcoma, a cancer affecting smooth muscle tissue. The study also aims to ensure the drug's safety for patients. Suitable candidates for this trial have RB1-negative leiomyosarcoma (a tumor type lacking a certain protein) and have previously tried at least one other cancer treatment. Participants must have a tumor that can be safely biopsied, excluding areas like bone metastases, and should be able to swallow pills. As a Phase 1 trial, this research focuses on understanding how REC-617 works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications. However, you cannot be on other investigational agents or medications that prolong QTc before starting the study treatment.

Research shows that REC-617, the treatment under study for leiomyosarcoma, remains in the early testing stages. Initial safety information from these studies is expected soon. As a Phase 1 trial, researchers primarily focus on determining if REC-617 is safe for humans. This phase assesses whether the treatment is well-tolerated and identifies potential side effects.

REC-617 is unique because it offers a new approach to treating leiomyosarcoma, a rare type of cancer. While current treatments like surgery, radiation, and chemotherapy focus on removing or destroying cancer cells, REC-617 is taken as a pill, providing a potentially less invasive option. Researchers are excited because it targets the cancer differently, possibly offering effectiveness with fewer side effects compared to traditional methods. This novel approach could pave the way for more convenient and targeted cancer treatments.

Research has shown that REC-617, the treatment under study in this trial, holds promise for treating leiomyosarcoma (LMS), a rare type of cancer. It targets CDK7, a protein that aids cancer cell growth. In early studies, some patients responded to the treatment even after other therapies failed. Specifically, one patient experienced benefits for over six months despite having advanced cancer. These early results suggest that REC-617 might help control LMS by inhibiting its growth.¹²⁶⁷⁸